Andrew Bellinger's Insider Trades & SAST Disclosures
Andrew Bellinger's most recent trade in Verve Therapeutics Inc was a trade of 180,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 14, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew Bellinger.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 182,800 | 182,800 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2022 | 36,000 | 179,994 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.87 per share. | 14 Dec 2022 | 36,000 | 42,629 | - | 2.9 | 103,320 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 22.95 per share. | 01 Dec 2022 | 865 | 6,629 | - | 23.0 | 19,852 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 10,000 | 86,995 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 39.90 per share. | 28 Oct 2022 | 10,000 | 6,629 | - | 39.9 | 399,000 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 28 Oct 2022 | 10,000 | 16,629 | - | 1.5 | 14,800 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2022 | 40,000 | 96,995 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 23 Sep 2022 | 40,000 | 46,629 | - | 1.5 | 59,200 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 35.31 per share. | 23 Sep 2022 | 36,798 | 9,831 | - | 35.3 | 1,299,304 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2022 | 20,000 | 23,198 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 23 Sep 2022 | 20,000 | 26,629 | - | 1.5 | 29,600 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 35.59 per share. | 23 Sep 2022 | 13,368 | 6,629 | - | 35.6 | 475,803 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 34.67 per share. | 23 Sep 2022 | 6,632 | 19,997 | - | 34.7 | 229,905 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 23 Sep 2022 | 3,202 | 6,629 | - | 36.0 | 115,380 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 20 Jul 2022 | 20,000 | 6,629 | - | 34.9 | 698,000 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2022 | 20,000 | 1,599 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 20 Jul 2022 | 20,000 | 26,629 | - | 1.4 | 27,800 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Sale of securities on an exchange or to another person at price $ 24.90 per share. | 13 Jul 2022 | 10,000 | 6,629 | - | 24.9 | 249,000 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 10,000 | 136,995 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | CSO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 13 Jul 2022 | 10,000 | 16,629 | - | 1.5 | 14,800 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 22 Dec 2021 | 15,000 | 20,000 | - | 1.5 | 22,200 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 15,000 | 146,995 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.60 per share. | 22 Dec 2021 | 8,161 | 9,871 | - | 38.6 | 315,031 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.37 per share. | 22 Dec 2021 | 4,871 | 5,000 | - | 39.4 | 191,795 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.42 per share. | 22 Dec 2021 | 1,968 | 18,032 | - | 37.4 | 73,643 | Common Stock |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 21,599 | 21,599 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Andrew Bellinger | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 17 Jun 2021 | 5,000 | 5,000 | - | 19 | 95,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges